Loading…

Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha

Evidence from both animal and human studies clearly supports the renal beneficial effects of empagliflozin (emp), a sodium glucose co-transporter 2 (SGLT2) inhibitor, but the mechanism in which it exerts its effect is not well understood. In this study, we investigated the capability of emp on reduc...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, metabolic syndrome and obesity metabolic syndrome and obesity, 2020-01, Vol.13, p.1953-1967
Main Authors: Ndibalema, Angelamellisy Revelian, Kabuye, Deo, Wen, Si, Li, Lulu, Li, Xin, Fan, Qiuling
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c642t-bb03dbe5ab9da1059763a7ae8ebc35f23a1d3faf4be2ba60c293c6ec36c48a463
cites cdi_FETCH-LOGICAL-c642t-bb03dbe5ab9da1059763a7ae8ebc35f23a1d3faf4be2ba60c293c6ec36c48a463
container_end_page 1967
container_issue
container_start_page 1953
container_title Diabetes, metabolic syndrome and obesity
container_volume 13
creator Ndibalema, Angelamellisy Revelian
Kabuye, Deo
Wen, Si
Li, Lulu
Li, Xin
Fan, Qiuling
description Evidence from both animal and human studies clearly supports the renal beneficial effects of empagliflozin (emp), a sodium glucose co-transporter 2 (SGLT2) inhibitor, but the mechanism in which it exerts its effect is not well understood. In this study, we investigated the capability of emp on reducing hyperglycemia-induced renal proximal tubular epithelial cells injury and we evaluated if the renoprotective effect of emp associates with hypoxia-inducible factor-1α (HIF-1α). Human kidney cell lines (HK-2 cells) were incubated in normoxia, high glucose with or without emp treatment for 72 hours to evaluate the induction of HIF-1α, glucose transporter-1, SGLT2, the fibrosis signal pathway and epithelial-mesenchymal transition (EMT) markers. High glucose (HG) increased expression of Collagen IV, Fibronectin, transforming growth factor-beta1 (TGF-β1). However, emp treatment remarkably decreased expression of TGF-β1, accumulation of extracellular matrix proteins (Fibronectin, Collagen IV), as well as (phosphorylated-smad3) P-smad3. HG increased SGLT2 protein expression compared to normal glucose (NG) while emp significantly decreased SGLT2 expression. Furthermore, emp decreased high glucose-induced alpha-smooth muscle actin (α-SMA) expression and reversed epithelial marker (E-catherin) suppression induced by high glucose. In addition, emp treatment for 72 h increased expression of HIF-1α protein (95% CI: -0.5918 to -0.002338, at 100nM, P < 0.05, 95% CI -0.6631 to -0.07367 at 500nM, P < 0.05) in hyperglycemic normoxic HK-2 cells. Furthermore, we observed increased expression of GLUT-1 protein after emp treatment and remarkably decreased cell proliferation. Emp treatment protected proximal renal tubular cells injury induced by high glucose. Induction of HIF-1α expression by emp may play an essential role in the protection of high glucose-induced proximal renal tubular epithelial cells injury.
doi_str_mv 10.2147/DMSO.S243170
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a643b230f7d6409eb67c42e9d3aa3e48</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A630710907</galeid><doaj_id>oai_doaj_org_article_a643b230f7d6409eb67c42e9d3aa3e48</doaj_id><sourcerecordid>A630710907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c642t-bb03dbe5ab9da1059763a7ae8ebc35f23a1d3faf4be2ba60c293c6ec36c48a463</originalsourceid><addsrcrecordid>eNptkl2LEzEUhgdR3GXdO68lIIgXTs0kadK5EUrd3RZWVtz1OpxkMtOUdFKTmcX6G_zRZtq6tGICOeHkOW84H1n2usAjUjDx8fOX-7vRPWG0EPhZdl4UYpILjMXzo_tZdhnjCg9LYEbIy-yMEo75ZDw-z35frTfQOFs7_8u26GvwndFdRNMGbBu7wfHTrsGhb6ZN50OvegcBzYxzaNGu-rBNpuq1qZDaorltlujG9dpHgx4tpKgm8Z31LfI1mm83SQ3yXYRVzqBr0J0PqMinbrOEV9mLGlw0lwd7kX2_vnqYzfPbu5vFbHqba85IlyuFaaXMGFRZQYHHpeAUBJiJUZqOa0KhqGgNNVOGKOBYk5JqbjTlmk2AcXqRLfa6lYeV3ISUYNhKD1buHD40EkJntTMSOKOKUFyLijNcGsWFZsSUFQWghk2S1qe91qZXa1Np03YB3Ino6Utrl7Lxj1KQUlBOk8D7g0DwP3oTO7m2Uaf6Qmt8HyVhRcmwmIhxQt_-g658H1JfdlSCcEGOqAZSAratffpXD6JyyikWBS6xSNToP1TalVlb7VtT2-Q_CXh3FLA04Lpl9K4fmhtPwQ97UAcfYzD1UzEKLIeplcPUysPUJvzNcQGf4L8zSv8ABb_nKg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2414070125</pqid></control><display><type>article</type><title>Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis_OA刊</source><source>Publicly Available Content Database</source><creator>Ndibalema, Angelamellisy Revelian ; Kabuye, Deo ; Wen, Si ; Li, Lulu ; Li, Xin ; Fan, Qiuling</creator><creatorcontrib>Ndibalema, Angelamellisy Revelian ; Kabuye, Deo ; Wen, Si ; Li, Lulu ; Li, Xin ; Fan, Qiuling</creatorcontrib><description>Evidence from both animal and human studies clearly supports the renal beneficial effects of empagliflozin (emp), a sodium glucose co-transporter 2 (SGLT2) inhibitor, but the mechanism in which it exerts its effect is not well understood. In this study, we investigated the capability of emp on reducing hyperglycemia-induced renal proximal tubular epithelial cells injury and we evaluated if the renoprotective effect of emp associates with hypoxia-inducible factor-1α (HIF-1α). Human kidney cell lines (HK-2 cells) were incubated in normoxia, high glucose with or without emp treatment for 72 hours to evaluate the induction of HIF-1α, glucose transporter-1, SGLT2, the fibrosis signal pathway and epithelial-mesenchymal transition (EMT) markers. High glucose (HG) increased expression of Collagen IV, Fibronectin, transforming growth factor-beta1 (TGF-β1). However, emp treatment remarkably decreased expression of TGF-β1, accumulation of extracellular matrix proteins (Fibronectin, Collagen IV), as well as (phosphorylated-smad3) P-smad3. HG increased SGLT2 protein expression compared to normal glucose (NG) while emp significantly decreased SGLT2 expression. Furthermore, emp decreased high glucose-induced alpha-smooth muscle actin (α-SMA) expression and reversed epithelial marker (E-catherin) suppression induced by high glucose. In addition, emp treatment for 72 h increased expression of HIF-1α protein (95% CI: -0.5918 to -0.002338, at 100nM, P &lt; 0.05, 95% CI -0.6631 to -0.07367 at 500nM, P &lt; 0.05) in hyperglycemic normoxic HK-2 cells. Furthermore, we observed increased expression of GLUT-1 protein after emp treatment and remarkably decreased cell proliferation. Emp treatment protected proximal renal tubular cells injury induced by high glucose. Induction of HIF-1α expression by emp may play an essential role in the protection of high glucose-induced proximal renal tubular epithelial cells injury.</description><identifier>ISSN: 1178-7007</identifier><identifier>EISSN: 1178-7007</identifier><identifier>DOI: 10.2147/DMSO.S243170</identifier><identifier>PMID: 32606855</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Angiotensin II ; animals ; Antidiabetics ; Bone morphogenetic proteins ; Canagliflozin ; Collagen ; Dapagliflozin ; Diabetes ; Diabetic nephropathies ; Empagliflozin ; Fibronectins ; Glucose ; humans ; Hyperglycemia ; Hypertension ; Hypoxia ; Kidney diseases ; Muscle proteins ; Original Research ; Proteins ; Stem cells ; transforming growth factor beta1 ; Transforming growth factors ; Type 2 diabetes ; Urine</subject><ispartof>Diabetes, metabolic syndrome and obesity, 2020-01, Vol.13, p.1953-1967</ispartof><rights>2020 Ndibalema et al.</rights><rights>COPYRIGHT 2020 Dove Medical Press Limited</rights><rights>2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Ndibalema et al. 2020 Ndibalema et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c642t-bb03dbe5ab9da1059763a7ae8ebc35f23a1d3faf4be2ba60c293c6ec36c48a463</citedby><cites>FETCH-LOGICAL-c642t-bb03dbe5ab9da1059763a7ae8ebc35f23a1d3faf4be2ba60c293c6ec36c48a463</cites><orcidid>0000-0002-9850-0702 ; 0000-0003-3448-2952 ; 0000-0003-2598-6075</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2414070125/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2414070125?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25733,27903,27904,36991,36992,44569,53769,53771,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32606855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ndibalema, Angelamellisy Revelian</creatorcontrib><creatorcontrib>Kabuye, Deo</creatorcontrib><creatorcontrib>Wen, Si</creatorcontrib><creatorcontrib>Li, Lulu</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Fan, Qiuling</creatorcontrib><title>Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha</title><title>Diabetes, metabolic syndrome and obesity</title><addtitle>Diabetes Metab Syndr Obes</addtitle><description>Evidence from both animal and human studies clearly supports the renal beneficial effects of empagliflozin (emp), a sodium glucose co-transporter 2 (SGLT2) inhibitor, but the mechanism in which it exerts its effect is not well understood. In this study, we investigated the capability of emp on reducing hyperglycemia-induced renal proximal tubular epithelial cells injury and we evaluated if the renoprotective effect of emp associates with hypoxia-inducible factor-1α (HIF-1α). Human kidney cell lines (HK-2 cells) were incubated in normoxia, high glucose with or without emp treatment for 72 hours to evaluate the induction of HIF-1α, glucose transporter-1, SGLT2, the fibrosis signal pathway and epithelial-mesenchymal transition (EMT) markers. High glucose (HG) increased expression of Collagen IV, Fibronectin, transforming growth factor-beta1 (TGF-β1). However, emp treatment remarkably decreased expression of TGF-β1, accumulation of extracellular matrix proteins (Fibronectin, Collagen IV), as well as (phosphorylated-smad3) P-smad3. HG increased SGLT2 protein expression compared to normal glucose (NG) while emp significantly decreased SGLT2 expression. Furthermore, emp decreased high glucose-induced alpha-smooth muscle actin (α-SMA) expression and reversed epithelial marker (E-catherin) suppression induced by high glucose. In addition, emp treatment for 72 h increased expression of HIF-1α protein (95% CI: -0.5918 to -0.002338, at 100nM, P &lt; 0.05, 95% CI -0.6631 to -0.07367 at 500nM, P &lt; 0.05) in hyperglycemic normoxic HK-2 cells. Furthermore, we observed increased expression of GLUT-1 protein after emp treatment and remarkably decreased cell proliferation. Emp treatment protected proximal renal tubular cells injury induced by high glucose. Induction of HIF-1α expression by emp may play an essential role in the protection of high glucose-induced proximal renal tubular epithelial cells injury.</description><subject>Angiotensin II</subject><subject>animals</subject><subject>Antidiabetics</subject><subject>Bone morphogenetic proteins</subject><subject>Canagliflozin</subject><subject>Collagen</subject><subject>Dapagliflozin</subject><subject>Diabetes</subject><subject>Diabetic nephropathies</subject><subject>Empagliflozin</subject><subject>Fibronectins</subject><subject>Glucose</subject><subject>humans</subject><subject>Hyperglycemia</subject><subject>Hypertension</subject><subject>Hypoxia</subject><subject>Kidney diseases</subject><subject>Muscle proteins</subject><subject>Original Research</subject><subject>Proteins</subject><subject>Stem cells</subject><subject>transforming growth factor beta1</subject><subject>Transforming growth factors</subject><subject>Type 2 diabetes</subject><subject>Urine</subject><issn>1178-7007</issn><issn>1178-7007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl2LEzEUhgdR3GXdO68lIIgXTs0kadK5EUrd3RZWVtz1OpxkMtOUdFKTmcX6G_zRZtq6tGICOeHkOW84H1n2usAjUjDx8fOX-7vRPWG0EPhZdl4UYpILjMXzo_tZdhnjCg9LYEbIy-yMEo75ZDw-z35frTfQOFs7_8u26GvwndFdRNMGbBu7wfHTrsGhb6ZN50OvegcBzYxzaNGu-rBNpuq1qZDaorltlujG9dpHgx4tpKgm8Z31LfI1mm83SQ3yXYRVzqBr0J0PqMinbrOEV9mLGlw0lwd7kX2_vnqYzfPbu5vFbHqba85IlyuFaaXMGFRZQYHHpeAUBJiJUZqOa0KhqGgNNVOGKOBYk5JqbjTlmk2AcXqRLfa6lYeV3ISUYNhKD1buHD40EkJntTMSOKOKUFyLijNcGsWFZsSUFQWghk2S1qe91qZXa1Np03YB3Ino6Utrl7Lxj1KQUlBOk8D7g0DwP3oTO7m2Uaf6Qmt8HyVhRcmwmIhxQt_-g658H1JfdlSCcEGOqAZSAratffpXD6JyyikWBS6xSNToP1TalVlb7VtT2-Q_CXh3FLA04Lpl9K4fmhtPwQ97UAcfYzD1UzEKLIeplcPUysPUJvzNcQGf4L8zSv8ABb_nKg</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Ndibalema, Angelamellisy Revelian</creator><creator>Kabuye, Deo</creator><creator>Wen, Si</creator><creator>Li, Lulu</creator><creator>Li, Xin</creator><creator>Fan, Qiuling</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9850-0702</orcidid><orcidid>https://orcid.org/0000-0003-3448-2952</orcidid><orcidid>https://orcid.org/0000-0003-2598-6075</orcidid></search><sort><creationdate>20200101</creationdate><title>Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha</title><author>Ndibalema, Angelamellisy Revelian ; Kabuye, Deo ; Wen, Si ; Li, Lulu ; Li, Xin ; Fan, Qiuling</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c642t-bb03dbe5ab9da1059763a7ae8ebc35f23a1d3faf4be2ba60c293c6ec36c48a463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Angiotensin II</topic><topic>animals</topic><topic>Antidiabetics</topic><topic>Bone morphogenetic proteins</topic><topic>Canagliflozin</topic><topic>Collagen</topic><topic>Dapagliflozin</topic><topic>Diabetes</topic><topic>Diabetic nephropathies</topic><topic>Empagliflozin</topic><topic>Fibronectins</topic><topic>Glucose</topic><topic>humans</topic><topic>Hyperglycemia</topic><topic>Hypertension</topic><topic>Hypoxia</topic><topic>Kidney diseases</topic><topic>Muscle proteins</topic><topic>Original Research</topic><topic>Proteins</topic><topic>Stem cells</topic><topic>transforming growth factor beta1</topic><topic>Transforming growth factors</topic><topic>Type 2 diabetes</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ndibalema, Angelamellisy Revelian</creatorcontrib><creatorcontrib>Kabuye, Deo</creatorcontrib><creatorcontrib>Wen, Si</creatorcontrib><creatorcontrib>Li, Lulu</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Fan, Qiuling</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Diabetes, metabolic syndrome and obesity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ndibalema, Angelamellisy Revelian</au><au>Kabuye, Deo</au><au>Wen, Si</au><au>Li, Lulu</au><au>Li, Xin</au><au>Fan, Qiuling</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha</atitle><jtitle>Diabetes, metabolic syndrome and obesity</jtitle><addtitle>Diabetes Metab Syndr Obes</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>13</volume><spage>1953</spage><epage>1967</epage><pages>1953-1967</pages><issn>1178-7007</issn><eissn>1178-7007</eissn><abstract>Evidence from both animal and human studies clearly supports the renal beneficial effects of empagliflozin (emp), a sodium glucose co-transporter 2 (SGLT2) inhibitor, but the mechanism in which it exerts its effect is not well understood. In this study, we investigated the capability of emp on reducing hyperglycemia-induced renal proximal tubular epithelial cells injury and we evaluated if the renoprotective effect of emp associates with hypoxia-inducible factor-1α (HIF-1α). Human kidney cell lines (HK-2 cells) were incubated in normoxia, high glucose with or without emp treatment for 72 hours to evaluate the induction of HIF-1α, glucose transporter-1, SGLT2, the fibrosis signal pathway and epithelial-mesenchymal transition (EMT) markers. High glucose (HG) increased expression of Collagen IV, Fibronectin, transforming growth factor-beta1 (TGF-β1). However, emp treatment remarkably decreased expression of TGF-β1, accumulation of extracellular matrix proteins (Fibronectin, Collagen IV), as well as (phosphorylated-smad3) P-smad3. HG increased SGLT2 protein expression compared to normal glucose (NG) while emp significantly decreased SGLT2 expression. Furthermore, emp decreased high glucose-induced alpha-smooth muscle actin (α-SMA) expression and reversed epithelial marker (E-catherin) suppression induced by high glucose. In addition, emp treatment for 72 h increased expression of HIF-1α protein (95% CI: -0.5918 to -0.002338, at 100nM, P &lt; 0.05, 95% CI -0.6631 to -0.07367 at 500nM, P &lt; 0.05) in hyperglycemic normoxic HK-2 cells. Furthermore, we observed increased expression of GLUT-1 protein after emp treatment and remarkably decreased cell proliferation. Emp treatment protected proximal renal tubular cells injury induced by high glucose. Induction of HIF-1α expression by emp may play an essential role in the protection of high glucose-induced proximal renal tubular epithelial cells injury.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>32606855</pmid><doi>10.2147/DMSO.S243170</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-9850-0702</orcidid><orcidid>https://orcid.org/0000-0003-3448-2952</orcidid><orcidid>https://orcid.org/0000-0003-2598-6075</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-7007
ispartof Diabetes, metabolic syndrome and obesity, 2020-01, Vol.13, p.1953-1967
issn 1178-7007
1178-7007
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a643b230f7d6409eb67c42e9d3aa3e48
source Open Access: PubMed Central; Taylor & Francis_OA刊; Publicly Available Content Database
subjects Angiotensin II
animals
Antidiabetics
Bone morphogenetic proteins
Canagliflozin
Collagen
Dapagliflozin
Diabetes
Diabetic nephropathies
Empagliflozin
Fibronectins
Glucose
humans
Hyperglycemia
Hypertension
Hypoxia
Kidney diseases
Muscle proteins
Original Research
Proteins
Stem cells
transforming growth factor beta1
Transforming growth factors
Type 2 diabetes
Urine
title Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T11%3A05%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Empagliflozin%20Protects%20Against%20Proximal%20Renal%20Tubular%20Cell%20Injury%20Induced%20by%20High%20Glucose%20via%20Regulation%20of%20Hypoxia-Inducible%20Factor%201-Alpha&rft.jtitle=Diabetes,%20metabolic%20syndrome%20and%20obesity&rft.au=Ndibalema,%20Angelamellisy%20Revelian&rft.date=2020-01-01&rft.volume=13&rft.spage=1953&rft.epage=1967&rft.pages=1953-1967&rft.issn=1178-7007&rft.eissn=1178-7007&rft_id=info:doi/10.2147/DMSO.S243170&rft_dat=%3Cgale_doaj_%3EA630710907%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c642t-bb03dbe5ab9da1059763a7ae8ebc35f23a1d3faf4be2ba60c293c6ec36c48a463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2414070125&rft_id=info:pmid/32606855&rft_galeid=A630710907&rfr_iscdi=true